News

Rinvoq reduces AS disease activity in 1 year of clinical trial

Treatment with Rinvoq (upadacitinib) substantially reduced disease activity for most adults with ankylosing spondylitis (AS) who had failed to respond to other treatments, according to one-year data from a clinical trial. “These 1-year data demonstrated consistent improvement and maintenance of response with [Rinvoq] treatment in treatment-refractory patients…

Cimzia clinical response, disease activity tied to productivity gains

Long-term use of Cimzia (certolizumab pegol) is associated with a higher clinical response to treatment and lower disease activity in people with axial spondyloarthritis (axSpA). This translated to increased productivity for patients, both at work and in household activities. “This highlights the importance of targeting these thresholds to limit…

TNF, IL-17 inhibitors work equally regardless of MRI, CRP tests: Study

People with axial spondyloarthritis (axSpA) respond equally well to two types of medications that ease inflammation — tumor necrosis factor (TNF) inhibitors or interleukin-17 (IL-17) inhibitors — regardless of their imaging findings or C-reactive protein (CRP) levels before treatment, a meta-analysis has found. This suggests that neither magnetic resonance imaging…

Genetics not found to influence Cosentyx treatment responses

The responses to Cosentyx (secukinumab) among people with ankylosing spondylitis (AS) and other inflammatory diseases aren’t significantly impacted by a person’s genetic background, a recent study suggests. The findings challenge an existing hypothesis that the variable responses to the therapy in clinical practice could largely be driven by…

Top-line data support Phase 3 trial of LNK01001 in hard-to-treat AS

An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…

Contents of cell cargo carriers may offer insights into AS biomarkers

Exosomes, which are tiny carriers for cellular cargo, are found to have significantly different contents in ankylosing spondylitis (AS) patients compared with healthy people, which in turn has marked influences on immune cell function, according to a recent study. Researchers specifically identified that the profile of molecules called microRNAs…

Ankylosing spondylitis genes, potential treatments ID’d: Study

Genes involved in ankylosing spondylitis (AS) as well as potential new therapies have been identified through a computer-based analysis, according to a study. The findings “contribute to our understanding of the molecular mechanisms underlying the onset and progression of AS. They also provide candidate targets for the diagnosis and…